Johnson & Johnson Offloads Rights For Hepatitis B Candidate To GSK
Portfolio Pulse from Vandana Singh
Johnson & Johnson's Janssen Pharmaceuticals has transferred exclusive worldwide rights to develop and commercialize JNJ-3989, a hepatitis B virus-targeted therapeutic, to GSK plc. The drug was initially in-licensed by Janssen from Arrowhead Pharmaceuticals in 2018. GSK will assume all rights and obligations of the existing license agreement, including financial obligations owed to Arrowhead. GSK will also be responsible for upfront and potential milestone-based payments to Janssen and Arrowhead, totaling approximately $1 billion.
October 31, 2023 | 3:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arrowhead Pharmaceuticals, the original licensor of JNJ-3989, will receive tiered royalties on net sales under the original agreement. This could potentially increase ARWR's future revenues.
The receipt of tiered royalties on net sales of JNJ-3989 under the original agreement could potentially increase ARWR's future revenues, which could have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
GSK has acquired the rights to develop and commercialize JNJ-3989, a hepatitis B therapeutic, from Janssen Pharmaceuticals. This could potentially strengthen GSK's late-stage pipeline of specialty medicines.
The acquisition of the rights to JNJ-3989 could potentially strengthen GSK's late-stage pipeline of specialty medicines, which could have a positive impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Janssen Pharmaceuticals, a Johnson & Johnson company, has transferred the rights to develop and commercialize JNJ-3989 to GSK. This could potentially reduce JNJ's future revenues from the drug.
The transfer of the rights to JNJ-3989 to GSK could potentially reduce JNJ's future revenues from the drug, which could have a negative impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100